68Ga-PSMA-11 PET/CT在根治性治疗后早期复发前列腺癌中的诊断效能与临床影响:前瞻性多中心研究(IAEA-PSMA研究)
该前瞻性多中心国际研究纳入17国1004例根治性治疗后生化复发且常规影像阴性的前列腺癌患者,行68Ga-PSMA-11 PET/CT并中央判读。65.1%患者PET/CT阳性,阳性率与Gleason评分、PET时PSA水平、PSA倍增时间及放疗作为初始治疗相关(P<0.001)。56.8%患者基于PET/CT结果改变了治疗管理,不同收入国家阳性率无统计学差异。
要点
- 根治后生化复发且常规影像阴性患者中,68Ga-PSMA-11 PET/CT阳性率达65.1%。
- PET/CT阳性与Gleason评分、PET时PSA水平、PSA倍增时间及初始放疗相关(P<0.001)。
- 56.8%患者基于PSMA PET/CT结果调整了治疗管理。
核心结论
- 68Ga-PSMA-11 PET/CT在生化复发前列腺癌中可检出多数患者的局部和转移性复发。
- PSMA PET/CT阳性率与Gleason评分、PET时PSA水平、PSA倍增时间及放疗作为初始治疗相关。
- PSMA PET/CT结果使超过半数患者的治疗管理发生改变。
- 该研究证明PSMA PET/CT在生化复发前列腺癌检查中具有可靠性和全球可行性。
研究设计与样本
- 前瞻性、多中心、国际研究,纳入15个国家17个中心的患者。
- 纳入标准为组织病理学证实的前列腺腺癌、既往接受初始治疗、临床确立的生化复发,且PSA 4-10 ng/mL患者常规影像(CT加骨显像)和MRI结果阴性。
- 所有患者接受68Ga-PSMA-11 PET/CT扫描,图像和数据集中判读。
- 采用多变量逻辑回归分析识别PSMA阳性结果的独立预测因子,变量包括Gleason评分、PET扫描时PSA水平、PSA倍增时间和初始治疗策略。
- 所有患者监测至少6个月。
主要发现
- 共1004例患者,77.7%初始接受根治性前列腺切除术,22.3%接受放疗。
- 总体65.1%患者PSMA PET/CT结果为阳性。
- PSMA PET/CT阳性与Gleason评分、PET扫描时PSA水平、PSA倍增时间及放疗作为初始治疗相关(P<0.001)。
- 56.8%患者基于PSMA PET/CT结果修改了治疗。
- 不同收入国家的PSMA PET/CT阳性率一致且无统计学差异。
临床怎么用
- 对根治性治疗后生化复发且常规影像阴性的前列腺癌患者,可行68Ga-PSMA-11 PET/CT以定位复发。
- PSMA PET/CT阳性结果可指导后续治疗调整,本研究中超过半数患者治疗管理因此改变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biochemical recurrence (BCR) is a clinical challenge in prostate cancer (PCa) patients, as recurrence localization guides subsequent therapies. The use of PET with prostate-specific membrane antigen (PSMA) provides better accuracy than conventional imaging practice. This prospective, multicenter, international study was performed to evaluate the diagnostic performance and clinical impact of PSMA PET/CT for evaluating BCR in PCa patients in a worldwide scenario. Methods: Patients were recruited from 17 centers in 15 countries. Inclusion criteria were histopathologically proven prostate adenocarcinoma, previous primary treatment, clinically established BCR, and negative conventional imaging (CT plus bone scintigraphy) and MRI results for patients with PSA levels of 4-10 ng/mL. All patients underwent PET/CT scanning with 68Ga-PSMA-11. Images and data were centrally reviewed. Multivariate logistic regression analysis was applied to identify the independent predictors of PSMA-positive results. Variables were selected for this regression model on the basis of significant associations in the univariate analysis and previous clinical knowledge: Gleason score, the PSA level at the time of the PET scan, PSA doubling time, and primary treatment strategy. All patients were monitored for a minimum of 6 mo. Results: From a total of 1,004 patients, 77.7% were treated initially with radical prostatectomy and 22.3% were treated with radiotherapy. Overall, 65.1% had positive PSMA PET/CT results. PSMA PET/CT positivity was correlated with the Gleason score, PSA level at the time of the PET scan, PSA doubling time, and radiotherapy as the primary treatment (P < 0.001). Treatment was modified on the basis of PSMA PET/CT results in 56.8% of patients. PSMA PET/CT positivity rates were consistent and not statistically different among countries with different incomes. Conclusion: This multicenter, international, prospective trial of PSMA PET/CT confirmed its capability for detecting local and metastatic recurrence in most PCa patients in the setting of BCR. PSMA PET/CT positivity was correlated with the Gleason score, PSA level at the time of the PET scan, PSA doubling time, and radiotherapy as the primary treatment. PSMA PET/CT results led to changes in therapeutic management in more than half of the cohort. The study demonstrated the reliability and worldwide feasibility of PSMA PET/CT in the workup of PCa patients with BCR.
引用
- Cerci JJ, Fanti S, Lobato EE, et al. Diagnostic Performance and Clinical Impact of 68Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study). J Nucl Med. 2021. PMID: 34215674. doi:10.2967/jnumed.120.261886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。